EMA Recommends Extension of Indications for Dostarlimab By Ogkologos - January 23, 2025 648 0 Facebook Twitter Google+ Pinterest WhatsApp Change concerns the first-line treatment of patients with endometrial cancer Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Experimental Treatment Uses Engineered Fat Cells to “Starve” Tumors March 27, 2025 EMA Recommends Granting a Marketing Authorisation for Ivosidenib March 1, 2023 Second-line Sintilimab Improves Survival Over Docetaxel in Squamous Non-Small Cell Lung... December 11, 2020 Bean there done that: Can swapping to pulses be the new... February 11, 2022 Load more HOT NEWS OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally... How Your Primary Care Provider Can Help You Throughout Your Cancer... Countdown to 100,000 OncoLife Survivorship Care Plans: What is a Survivorship... ctDNA Detection After Initial Treatment of Early-Stage NSCLC Has Potential to...
